GSK touts record Shingrix sales as Zantac cases go to trial
Months after GSK changed its name from GlaxoSmithKline and spun off its consumer health division into the standalone Haleon, the Big Pharma is reporting better-than-expected sales — with both opportunities and challenges ahead.
CEO Emma Walmsley touted record sales of shingles vaccine Shingrix on the earnings call Wednesday, noting that the vaccine recorded £760 million in sales for the quarter — over $800 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.